TABLE 3.
Demographics of pks+ versus pks− subjects.
| Demographic | pks+ (N = 15) | pks− (N = 248) | p Value |
|---|---|---|---|
| Age | 64 (62–67) | 65 (61–68) | 0.82 |
| Race/ethnicity | 0.23 | ||
| Black | 0 (0%) | 34 (14%) | |
| Non-Black | 15 (100%) | 217 (87%) | |
| Prostate-specific antigen | 5.6 (4.5–6.5) | 5.2 (4.3–6.7) | 0.57 |
| Previous prostate biopsy | 3 (20%) | 40 (16%) | 0.71 |
| Prostate cancer family history | 2 (13%) | 45 (18%) | 1 |
| Prostate cancer prevention trial risk calculator (%) | 27% (24%−32%) | 28% (25%−32%) | 0.25 |
| PCA3 | 31.1 (8.5–42.6) | 31.1 (13.8–61.6) | 0.36 |
| T2:Erg | 5.5 (0.9–27.7) | 4.7 (0.1–34.2) | 0.6 |
| Any prostate cancer | 6 (40%) | 126 (51%) | 0.44 |
| Clinically significant prostate cancer (grade group >1) | 1 (7%) | 68 (27%) | 0.1 |
| Copresence with other genotoxins | |||
| cnfl | 4 (27%) | 2 (0.8%) | <0.001 |
| cdt | 5 (33%) | 2 (0.8%) | <0.001 |